2026 Update from a UK-trained gastroenterologist in Dubai.
In my 25 years of clinical practice, working in London and now in Dubai, one of the most important developments in inflammatory bowel disease has been the shift toward targeted therapies based on specific inflammatory pathways.
Icotrokinra is a new oral peptide currently being researched, targeting the IL-23 pathway, which plays a central role in both Crohn’s disease and ulcerative colitis.
This is the same pathway used by established biologic therapies such as:
- Skyrizi (risankizumab)
- Omvoh (mirikizumab)
- Tremfya (guselkumab)
It is being developed as a once-daily oral treatment, rather than an injection or infusion.
Video Overview
Current Status
Icotrokinra has been approved by the FDA (March 2026) for psoriasis.
However, it is not currently available for Crohn’s disease or ulcerative colitis.
It is being studied in Phase 3 trials:
- ICONIC-UC
- ICONIC-Crohn’s
Timeline
Full data and potential approval are unlikely before 2028
Recommended Guides
Biologic Treatment
- Biologic Medicines & Treatment Options
- How Biologics Work in Crohn’s & Colitis
- Predicting Biologic Treatment Success
- Stelara vs Skyrizi Crohn’s Study
- Vedolizumab Response in IBD
- Tremfya Explained
- Rinvoq in Crohn’s & UC
FAQ
Is icotrokinra available for Crohn’s or ulcerative colitis?
No, it is not yet approved for IBD.
Is this a biologic?
It is an oral peptide targeting the same IL-23 pathway.
When might it be available?
Likely not before 2028.
If you wish to discuss this further or would like to make an appointment, please use the booking form on this page.